CytoDyn Signs On For Joint Venture In China

SANTA FE, N.M.--(BUSINESS WIRE)--Feb. 14, 2006--CytoDyn, Inc. (OTCBB:CYDY) has signed a letter of intent with Timeway International for a joint venture in China. The anticipated joint venture would develop Cytolin(R), CytoDyn's targeted immune therapy for HIV/AIDS, in this populous and economically expanding Asian nation. Timeway International has its principle offices in Phoenix, Hong Kong, Bejing, and Shanghai. It has joined with a select few U.S. biotech firms in order to bring a variety of advanced, non-competing medical technologies to the Chinese people, according to that Company's profile and its President, Philip Liu.